{"disease":{"id":"tenosynovial-giant-cell-tumor","name":"Tenosynovial giant cell tumor","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"vimseltinib","indication_name":"symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Romvimza","generic_name":"VIMSELTINIB","company_name":"Deciphera Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Romvimza works by blocking a specific enzyme that helps cancer cells grow and survive."},{"drug_id":"turalio","indication_name":"Tenosynovial giant cell tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TURALIO™","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1, Aurora kinase B, Cyclin-dependent kinase 19","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Turalio works by inhibiting a specific biological pathway."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04192344","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"Abbisko Therapeutics Co, Ltd","has_results":false},{"nct_id":"NCT02371369","title":"Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT04488822","title":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":true},{"nct_id":"NCT01643850","title":"MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04526704","title":"Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT04635111","title":"A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT07499362","title":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT05349643","title":"A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"AmMax Bio, Inc.","has_results":false},{"nct_id":"NCT04731675","title":"An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"AmMax Bio, Inc.","has_results":true},{"nct_id":"NCT04703322","title":"A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":true},{"nct_id":"NCT04938180","title":"A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"AmMax Bio, Inc.","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}